drugset / Trial / NCT05409300
Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea
Phase 2
Unknown
200 enrolled
ANRS, Emerging Infectious Diseases
APHP · collabAgence Nationale de Sécurité Sanitaire de la Guinée (ANSS Guinée) · collabAlliance for International Medical Action · collabCEPI · collabCentre National de Formation et de Recherche en Sante Rurale · collabInnovative clinical research network in vaccinology (IREIVAC) · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
NaSingle-groupOpen-labelPrevention
Summary
Phase II, non-randomized, open-label, comparative, single center national trial in Guinea, aimed to assess the humoral vaccine immune response induced by BBIBP-CorV vaccine in 200 adults aged between 18 and 45 years or 55 or older, one month after receiving the complete COVID-19 vaccination schedule.
Timeline
- Start
- 2022-04-25
- Primary completion
- 2023-08-03
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBIBP-CorV | Vaccine | 0.5 ml | Intramuscular |